Quest Diagnostics and Paige has announced a collaboration designed to unlock the potential of artificial intelligence (AI) to improve and speed up the diagnosis of cancer and other diseases that rely on pathologic assessment.
The collaboration involves analysis using Paige’s machine learning expertise of pathology diagnostic data and digitised slides from Quest Diagnostics and its AmeriPath and Dermpath businesses to uncover markers of cancer and other diseases. Using these insights, the parties intend to develop new software products which, following regulatory approval, will be marketed to pathologists, oncologists and other providers to support disease diagnosis. Near term, the parties also intend to license the insights to biopharmaceutical and research organisations to aid biomarker discovery, drug research and development and companion diagnostics.
The collaboration will initially focus on solid tumour cancers, such as prostate, breast, colorectal and lung. The agreement involves shared revenue for achieving certain product and commercial milestones and, assuming regulatory approval, arrangements for Quest to use approved software products in its pathology operations as well as joint marketing and research. Quest’s pathologists will aid in defining pathology workflows for using the products to support diagnostic decision-making. Additional terms were not disclosed.
Kristie Dolan, general manager, oncology franchise, Quest Diagnostics, said: ”As the leader in advanced diagnostics, we are excited to actively participate in the creation and use of new technologies that further the mission to make precision medicine clinically accessible, actionable and economical. We are energised about contributing our expertise to Paige’s computational pathology leadership to deliver insights from leading-edge technologies to improve the diagnosis of cancer and other diseases.”
The collaboration combines Quest’s leadership in advanced diagnostics, pathology subspecialty expertise and national scale with Paige’s leading AI-based software capabilities and proprietary data from millions of digitised pathology slides and associated therapy information. Quest and its specialty pathology businesses bring subspecialty expertise based largely from serving community cancer centres, which provide 80% of cancer care nationally, complementing insights from Paige’s academic centre expertise.
Leo Grady, chief executive officer of Paige, said: “We are excited to collaborate with Quest to create new software products that can deliver faster, more accurate and more informed clinical insights to patients than what is possible today. Given Quest’s vast footprint in the diagnostic space this collaboration will enable us to ensure broad adoption of the clinical products and biomarkers we’re building.”
Cancer diagnosis typically involves visual inspection of tumour tissue on a glass slide by a pathologist using a microscope. In contrast, AI-enabled computational pathology can identify known patterns in tissue that characterise disease as well as identify new markers, including those that are not necessarily detected by the naked eye. Because AI systems improve with exposure to new data, the data from Quest’s deep sub-specialised expertise aims to enhance Paige’s efforts to discern new insights that may improve cancer diagnosis and patient care.
